Translation and Innovation Unit

With a profound translational orientation, Cima Universidad de Navarra closes the loop between academia and industry by facilitating the transformation of its most promising research results into new drugs that benefit patients.

To this end, in a context of open innovation, Cima actively collaborates with other national and international research centers, venture capital funds, pharmaceutical and biotech companies or other private investors focused on early stage clinical trials.

Cima focuses its efforts on the development of a dynamic pipeline of patent-protected assets for the development of new drugs. Thus, our discoveries generate therapeutic and diagnostic alternatives that aim to meet the current needs of patients.

Among our most recent milestones is the licensing of several technologies for the treatment of rare and neurological diseases through gene therapy. In turn, we have licensed other molecules for the treatment of oncological and cardiovascular diseases, all through the creation of new biotechnology companies in which Cimas is a co-founder.

Cima also establishes alliances with other agents making its technology accessible in research of new molecular therapies, aptamers, in vitro and in vivo models, etc.

All this effort is aimed at reducing the risk intrinsic to drug development. Therefore, through the joint work of its extensive and consolidated research programs, Cima innovates in the development of new drugs and therapies.

To make these partnerships possible, Cima has the Translational and Innovation Unit, a team dedicated to the proper management of any application of Cima's research with the potential to benefit the patient. Thus, the center fulfills its translational mission: to bring scientific discoveries from the laboratory to the patient and vice versa.